FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 18025-1014	SERIAL NO 09/887,49		TENT TIPE T	M
APPLICANT Banerjee <i>et al.</i>			80)EIN
FILING DATE	GROUP	8	00%	<u> </u>

1617

June 22, 2001

ane and							U.	S. P	ATE	NT DOCU	MENTS			
EXAMIN	NER		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
Ma	7	Α	3	9	2	9	7	6	8	12/30/75	Brattsand et al	260	239.55	05/14/73
	1	В	3	9	9	4	9	7	4	11/30/76	Murakami et al	260	562	05/07/74
		С	4	3	3	5	1	2	1	06/15/82	Phillipps et al	424	241	02/13/81
	ů.	D	5	0	3	3	2	5	2	07/23/91	Carter	53	425	07/30/90
		E	5	0	5	2	5	5	8	10/01/91	Carter	206	439	07/27/90
		F	5	3	2	3	9	0	7	06/28/94	Kalvelage	206	531	03/15/93
		G	5	5	2	5	6	2	3	06/11/96	Spear et al	514	423	03/11/94
0		Н	5	6	0	2	1	1	0	02/11/97	Drumm et al	514	47	01/26/95
		1	5	6	5	4	2	7	6	08/05/97	Barrett et al	514	13	06/07/95
		7	5	6	6	8	1	1	0	09/16/97	Barrett et al	514	13	06/07/95
		Κ	5	6	7	4	8	6	0	10/07/97	Carling et al	514	171	10/03/94
		اـ	5	6	7	7	2	8	0	10/14/97	Barrett et al	514	14	06/07/95
		М	5	6	7	7	8	0	9	10/14/97	Kadlec	360	78.09	06/01/95
		N	5	6	8	3	9	8	3	11/04/97	Barrett et al	514	1:2	06/07/95
		0	5	6	9	1	3	3	6	11/25/97	Dorn et al	514	236.2	09/08/95
		Р	5	7	3	3	5	2	6	03/31/98	Trevino et al	424	9.52	12/14/95
		Q	5	7	5	0	5	4	9	05/12/98	Caldwell et al	514	364	10/15/96
		R	5	7	8	0	4	6	7	07/14/98	Dorn et al	514	236.2	08/08/97
		S	5	7	9	5	5	6	4	08/18/98	Aberg et al	424	45	03/07/96
		Т	5	8	7	4	4	8	1	02/23/99	Weers et al	514	761	06/07/95
		U	5	8	7	7	1	9	1	03/02/99	Caldwell et al	514	337	10/22/97
		V	5	9	2	9	0	9	4	07/27/99	Durette et al	514	340	10/22/97
		W	5	9	6	5	6	2	2	10/12/99	Senanayake	514	653	06/23/98
M	\	Х	5	9	7	2	9	1	9	10/26/99	Carling et al	514	171	10/07/97

EXAMINER

DATE CONSIDERED

04/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496	H		卫
APPLICANT Banerjee <i>et al.</i>		CENTE	2 B 3	CE
FILING DATE June 22, 2001	GROUP 1617	R 1600	0 200	
	· -	729	73	

POATE CANCELLED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL				DATE	NAME	CLASS	SUB CLASS	FILING DATE					
M	Υ	6	0	0	4	5	3	7	12/21/99	Blondino et al	424	45	12/18/98
	Z	6	0	4	0	3	4	4	03/21/00	Gao et al	514	554	05/21/98
	АА	6	0	4	1	7	7	7	03/28/00	Faithfull et al	128	200.24	12/01/95
	АВ	6	0	6	8	8	3	3	05/30/00	Aberg et al	424	45	08/18/98
	AC	6	0	7	1	9	7	1	06/06/00	Senanayake	514	653	05/05/99
	AD	6	1	2	6	9	1	9	10/03/00	Stefely et al	424	45	02/07/97
	AE	6	1	3	6	6	0	3	10/24/00	Dean et al	435	375	03/26/99
	AF	6	1	5	0	4	1	8	11/21/00	Hochrainer et al	514	630	11/12/99
Mb	AG	6	1	6	1	5	3	6	12/19/00	Redmon et al	128	200.14	10/07/98

FOREIGN PATENT DOCUMENTS

-			D	OCUM	IENT I	NUMB	ER		DATE	COUNTRY	CLASS	SUB CLASS	Trans Yes	slation No
MS	АН	2	3	0	5	0	9	2	02/02/73	Germany				
1	Al	9	9	0	0	1	3	4	07/01/99	РСТ				
MA	AJ	9	9	3	6	0	9	5	22/07/99	РСТ				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MS	AK	Bartow and Brogden, "An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma," <i>Drugs</i> , 55(2):303-322 (1998)
	AL	Campbell <i>et al</i> , "A comparison of the efficacy of long-acting B2-agonists: eformoterol via Turbohaler(R) and salmeterol via pressurized metered dose inhaler or Accuhaler (R), in mild to moderate asthmatics," <i>Respiratory Medicine</i> , 93:236-244 (1999)
	АМ	Dellamary <i>et al</i> , "Hollow Porous Particles in Metered Dose Inhalers," <i>Pharmaceutical Research</i> , 17(2):168-174 (2000)
	AN	Derwent# 000971705, WPI Acc. No. 1973-48969U/197335 citing German Patent Application No. DE 2305092 A, "Alpha-aminomethylbenzyl alcohol derivsprepd. by redn. of corresponding protected derivs."

EXAMINER

Mil 1

DATE CONSIDERED

04/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE

SERIAL NO. ATTY. DOCKET NO. 18025-1014 09/887,496 **C APPLICANT** Banerjee et al. FILING DATE **GROUP** June 22, 2001 1617

EQTEMENT.

	<u> </u>	OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
MATERITA	АО	Ekstrom <i>et al</i> , "Low-dose formoterol Turbuhaler(R) (Oxis(R)) b.i.d., a 3-month placebocontrolled comparison with terbutaline (q.i.d.)," <i>Respiratory Medicine</i> , <u>92:</u> 1040-1045 (1998)
	AP	Kaumann and Lemoine, "Direct labelling of myocardial B1-adrenoceptors; Comparison of binding affinity of 3H-()-bisoprolol with its blocking potency," <i>Archives of Pharmacology</i> , 331:27-39 (1985)
	AQ	Lecaillon <i>et al</i> , "Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder Inhalation via aerolizer (TM)," <i>European Journal Clinical Pharmacology</i> , <u>55:</u> 131-138 (1999)
	AR	Lemoine et al, "Direct labelling of B2-adrenoceptors; Comparison of binding potency of 3H-ICI 118,551 and blocking potency of ICI 118,551," Archives of Pharmacology, 331:40-51 (1985)
	AS	Lotvall <i>et al</i> , "Similar bronchodilation with formoterol delivered by Aerolizer or Turbuhaler," <i>Can Respir J</i> , 6(5):412-416 (1999)
	AT	Nielsen <i>et al</i> , "Flow-dependent effect of formoterol dry-powder inhaled from the Aeolizer (R)," <i>Eur Respir J</i> , 10:2105-2109 (1997)
	AU	Nightingale <i>et al</i> , "Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma," <i>Am J Respir Crit Care Med</i> , <u>159:</u> 1786-1790 (1999)
-	AV	Nogrady, T., (editor), Medicinal Chemistry: A Biochemical Approach, 388-392 (1985)
	AX	Palmqvist <i>et al</i> , "Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency," <i>Eur Respir J</i> , 10:2484-2489 (1997)
	AY	Rico-Mendez <i>et al</i> , "Formoterol en polvo seco, dos veces al dia versus salbutamol aerosol, cuatro veces al dia, en pacientes con asma estable," <i>Revista Alergia Mexico</i> , XLVI(5):130-135 (1999)
	AZ	Ringdal et al, "Onset and duration of action of single doses of formoterol inhaled via Turbuhaler(R)," Respiratory Medicine, 92:1017-1021 (1998)
	ВА	Schreurs <i>et al</i> , "A dose-repsonse study with formoterol Turbuhaler(R) as maintenance therapy in asthmatic patients," <i>Eur Respir J</i> , 9:1678-1683 (1996)
	ВВ	Seberova and Andersson, "Oxis(R) (formoterol given by Turbuhaler(R)) showed as rapid an onset of action as salbutamol given by a pMDI," <i>Respiratory Medicine</i> , 94:607-611 (2000)
Mb	вс	Selroos <i>et al</i> , "Delivery Devices for Inhaled Asthma Medication," <i>Clin Immunother</i> , <u>6:</u> 273-299 (1996)

EXAMINER

DATE CONSIDERED

04/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

LIST OF RATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE

STATEMENT

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

W .	BD	Tomioka <i>et al</i> , "Anti-Allergic Activities of the B-Adrenoceptor Stimulant Formoterol (BD 40A)," <i>Arch Int Pharmacodyn</i> , <u>250:</u> 279-292 (1981)
	BE	Totterman <i>et al</i> , "Tolerability to high doses of formoterol and terbutaline via Turbuhaler(R) for 3 days in stable asthmatic patients," <i>Eur Respir J</i> , <u>12:</u> 573-579 (1998)
MA	BF	Ullman <i>et al</i> , "Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study," <i>Allergy</i> , 51:745-748 (1996)

EXAMINER

24/5/0

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.